First Tracks Biotherapeutics (TRAX)

• Market cap: $1.38B
• 1 day: -1.53%
• 5 days: 6.72%
• 1 month: -12.03%
• 3 months: 121.58%
• 6 months: 103.16%
• Year to date: 103.16%
• 1 year: 103.16%
• 5 years: 103.16%
• 10 years: 103.16%
• Sector: Healthcare
• Industry: Biotechnology

About: First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.